Angiotensin-receptor blockers (ARBs) and risk of Alzheimer’s disease: a systematic review and meta-analysis

Teodoro J Oscanoa1,3, Jose Amado1,3, Xavier Vidal4 and Roman Romero-Ortuno5
1Universidad de San Martin de Porres, Peru
2Hospital Almenara - EsSalud, Peru
3Universidad Nacional Mayor de San Marcos, Peru
4Vall d’Hebron Hospital, Barcelona, Spain
5Trinity College Dublin, Discipline of Medical Gerontology, Mercer’s Institute for Successful Ageing, St James’s Hospital, Ireland

Statement of the Problem: Antihypertensive medications may reduce the incidence of cognitive disorders. This may be due to reasons beyond their pure hypotensive effect and could be different between antihypertensive classes. In this regard, angiotensin-receptor blockers (ARBs) have attracted scientific interest. The aim of the present study was to conduct a systematic review and meta-analysis of the reported association between the use of ARBs and the incidence of Alzheimer’s disease (AD).

Methodology: We systematically searched studies in PubMed, Cochrane Library and Google Scholar, since 1995 (date of approval of the first ARB by FDA) up to November 2018. We included randomized controlled trials (RCTs) or observational studies reporting the association between ARB use and incidence of AD in adults aged ≥18 years. The quality of studies was appraised according to the Newcastle-Ottawa Quality Assessment Scale (NOS).

Findings: Nine studies (1 RCT, 2 case-control studies and 6 cohort studies) met the inclusion criteria (total number of participants: 923,906; mean age 70.8 (range: 57.6-82.4) years; mean follow-up 7.5 (range: 4-20) years; mean NOS 7.4. When all studies were analyzed, ARB use was associated with a reduced risk of incident AD (HR 0.64, 95% CI 0.50-0.81, p <0.001). In the 4 studies reporting a mean participants’ age of ≥75 years (n= 856,506), the reduction in AD risk seemed greater (HR 0.52, 95% CI 0.34-0.80, p <0.001); in the 4 studies where mean age was <75 years (n=67,251), the risk reduction did not seem significant (HR 0.76, 95% CI 0.48-1.21, p= 0.250). The risk reduction seemed greater in European studies (n= 41,192; HR 0.56, 95% CI 0.41-0.77, p <0.001) than in American (n= 821,712; HR 0.52, 95% CI 0.26-1.01, p= 0.054) or Asian (n= 61,002; HR 0.74, 95% CI 0.43-1.28, p= 0.285) studies.

Conclusion & Significance: ARB use may reduce the risk of incident AD, especially in Europeans aged >75 years. This association does not imply causation and further research is required to clarify potential mechanisms.

References:

2. Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized


Biography

Teodoro J Oscanoa PhD leads the Research Center of Drug Safety in The Faculty of Medicine at University of San Martin de Porres, Lima, Peru. He is the head of the Department of Internal Medicine at Hospital Almenara and Associate Professor of Pharmacology in Universidad Nacional Mayor de San Marcos in Lima. His research areas are Geriatric Pharmacology, Drug Safety and Pharmacogenetics.

toscanoae@usmp.pe

Notes: